7.5亿license in,中国药企海外挣钱海外花

动脉新医药
20 Nov 2024

11月20日,君实生物发布公告,与未公开的许可方签署《许可协议》,获取许可方授权在大中华区(包括中国大陆、香港特别行政区、澳门特别行政区及台湾地区)内开发、制造、使用、进口、出口、销售和以其他任何方式商业化两款双靶点融合蛋白的独占许可权利和分许可权利。本次交易标的是两款双靶点融合蛋白,主要用于恶性肿瘤治疗。目前许可产品1处于海外I期临床试验阶段,君实生物已向国家药品监督管理局提交其在国内的I期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10